Clinical trial
A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared With Its Placebo in Male or Female Alopecia Areata Participants Aged 18 Years and Older With 30% or Greater Scalp Hair Loss
NCT05865041 is registered in ClinicalTrials.gov with ASLAN Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Parallel Group Treatment, Phase 2a, Double-blind, Two-arm Study to Investigate the Efficacy and Safety of Farudodstat Tablets Compared With Its Placebo in Male or Female Alopecia Areata Participants Aged 18 Years and Older With 30% or Greater Scalp Hair Loss
- Lead sponsor
- ASLAN Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 14, 2023
- Completion date
- October 31, 2024
- Enrollment
- 60 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.